MPH, Ph.D., Director, Oncology Biomarker Research, Eisai Inc.
Dr. Sachdev, Director of Oncology Biomarker Research at Eisai, a human health care (hhc) company, supports the clinical development of a diverse in-house pipeline of oncology compounds. During her time at Eisai, Dr. Sachdev has increasingly focused on cross-functional and global coordination of biomarker research activities to support the development of targeted therapeutics by alignment of drug and diagnostic strategies to achieve the oncology pipeline clinical objectives. Previously, Dr. Sachdev was a scientist at The Rockefeller University focusing on stem cell biology, cancer signaling networks and systems biology. Dr. Sachdev received her B.S. from Cornell University, her Ph.D. in Biochemistry and Molecular Biology from Mount Sinai-New York University School of Medicine. She has co-authored numerous research publications in the fields of cancer signaling networks, cancer genomics and personalized medicine and presented at international scientific conferences.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Deep NGS-based molecular and immune-infiltrate characterization and subtyping of tumors has the potential to identify molecular subsets that will benefit from immunotherapy as well as propose combination therapy to target single-agent resistance pathways. This session will showcase the utility of molecular subtyping to aid clinical drug development.